Skip to main content
Top
Published in: Molecular Neurodegeneration 1/2011

Open Access 01-12-2011 | Research article

Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease

Authors: Jeffrey B Carroll, Amber L Southwell, Rona K Graham, Jason P Lerch, Dagmar E Ehrnhoefer, Li-Ping Cao, Wei-Ning Zhang, Yu Deng, Nagat Bissada, R Mark Henkelman, Michael R Hayden

Published in: Molecular Neurodegeneration | Issue 1/2011

Login to get access

Abstract

Background

Huntington Disease (HD) is a neurodegenerative disorder in which caspase activation and cleavage of substrates, including the huntingtin protein, has been invoked as a pathological mechanism. Specific changes in caspase-2 (casp2) activity have been suggested to contribute to the pathogenesis of HD, however unique casp2 cleavage substrates have remained elusive. We thus utilized mice completely lacking casp2 (casp2-/-) to examine the role played by casp2 in the progression of HD. This 'substrate agnostic' approach allows us to query the effect of casp2 on HD progression without pre-defining proteolytic substrates of interest.

Results

YAC128 HD model mice lacking casp2 show protection from well-validated motor and cognitive features of HD, including performance on rotarod, swimming T-maze, pre-pulse inhibition, spontaneous alternation and locomotor tasks. However, the specific pathological features of the YAC128 mice including striatal volume loss and testicular degeneration are unaltered in mice lacking casp2. The application of high-resolution magnetic resonance imaging (MRI) techniques validates specific neuropathology in the YAC128 mice that is not altered by ablation of casp2.

Conclusions

The rescue of behavioral phenotypes in the absence of pathological improvement suggests that different pathways may be operative in the dysfunction of neural circuitry in HD leading to behavioral changes compared to the processes leading to cell death and volume loss. Inhibition of caspase-2 activity may be associated with symptomatic improvement in HD.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference The Huntington's Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993, 72 (6): 971-983. 10.1016/0092-8674(93)90585-E.CrossRef The Huntington's Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993, 72 (6): 971-983. 10.1016/0092-8674(93)90585-E.CrossRef
3.
go back to reference Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP: Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985, 44 (6): 559-577. 10.1097/00005072-198511000-00003.PubMedCrossRef Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP: Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol. 1985, 44 (6): 559-577. 10.1097/00005072-198511000-00003.PubMedCrossRef
4.
go back to reference Kumar S: Caspase function in programmed cell death. Cell Death Differ. 2007, 14 (1): 32-43. 10.1038/sj.cdd.4402060.PubMedCrossRef Kumar S: Caspase function in programmed cell death. Cell Death Differ. 2007, 14 (1): 32-43. 10.1038/sj.cdd.4402060.PubMedCrossRef
5.
go back to reference Galluzzi L, Joza N, Tasdemir E, Maiuri MC, Hengartner M, Abrams JM, Tavernarakis N, Penninger J, Madeo F, Kroemer G: No death without life: vital functions of apoptotic effectors. Cell Death Differ. 2008, 15 (7): 1113-1123. 10.1038/cdd.2008.28.PubMedPubMedCentralCrossRef Galluzzi L, Joza N, Tasdemir E, Maiuri MC, Hengartner M, Abrams JM, Tavernarakis N, Penninger J, Madeo F, Kroemer G: No death without life: vital functions of apoptotic effectors. Cell Death Differ. 2008, 15 (7): 1113-1123. 10.1038/cdd.2008.28.PubMedPubMedCentralCrossRef
6.
go back to reference Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, et al: Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ. 2004, 11 (4): 424-438. 10.1038/sj.cdd.4401358.PubMedCrossRef Hermel E, Gafni J, Propp SS, Leavitt BR, Wellington CL, Young JE, Hackam AS, Logvinova AV, Peel AL, Chen SF, et al: Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease. Cell Death Differ. 2004, 11 (4): 424-438. 10.1038/sj.cdd.4401358.PubMedCrossRef
7.
go back to reference Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, et al: Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci. 2002, 22 (18): 7862-7872.PubMed Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, et al: Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease. J Neurosci. 2002, 22 (18): 7862-7872.PubMed
8.
go back to reference Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, Hackam A, Sharp A, Thornberry N, et al: Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem. 2000, 275 (26): 19831-19838. 10.1074/jbc.M001475200.PubMedCrossRef Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, Hackam A, Sharp A, Thornberry N, et al: Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem. 2000, 275 (26): 19831-19838. 10.1074/jbc.M001475200.PubMedCrossRef
9.
go back to reference Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, McCutcheon K, Salvesen GS, Propp SS, Bromm M, et al: Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem. 1998, 273 (15): 9158-9167. 10.1074/jbc.273.15.9158.PubMedCrossRef Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, Singaraja R, McCutcheon K, Salvesen GS, Propp SS, Bromm M, et al: Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem. 1998, 273 (15): 9158-9167. 10.1074/jbc.273.15.9158.PubMedCrossRef
10.
go back to reference Weidemann A, Paliga K, Dürrwang U, Reinhard FB, Schuckert O, Evin G, Masters CL: Proteolytic processing of the Alzheimer's disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases. J Biol Chem. 1999, 274 (9): 5823-5829. 10.1074/jbc.274.9.5823.PubMedCrossRef Weidemann A, Paliga K, Dürrwang U, Reinhard FB, Schuckert O, Evin G, Masters CL: Proteolytic processing of the Alzheimer's disease amyloid precursor protein within its cytoplasmic domain by caspase-like proteases. J Biol Chem. 1999, 274 (9): 5823-5829. 10.1074/jbc.274.9.5823.PubMedCrossRef
11.
go back to reference Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, et al: Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell. 1999, 97 (3): 395-406. 10.1016/S0092-8674(00)80748-5.PubMedCrossRef Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, et al: Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell. 1999, 97 (3): 395-406. 10.1016/S0092-8674(00)80748-5.PubMedCrossRef
12.
go back to reference LeBlanc A, Liu H, Goodyer C, Bergeron C, Hammond J: Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease. J Biol Chem. 1999, 274 (33): 23426-23436. 10.1074/jbc.274.33.23426.PubMedCrossRef LeBlanc A, Liu H, Goodyer C, Bergeron C, Hammond J: Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer's disease. J Biol Chem. 1999, 274 (33): 23426-23436. 10.1074/jbc.274.33.23426.PubMedCrossRef
13.
go back to reference Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, et al: Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA. 2003, 100 (17): 10032-10037. 10.1073/pnas.1630428100.PubMedPubMedCentralCrossRef Gamblin TC, Chen F, Zambrano A, Abraha A, Lagalwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, et al: Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci USA. 2003, 100 (17): 10032-10037. 10.1073/pnas.1630428100.PubMedPubMedCentralCrossRef
14.
go back to reference Young JE, Gouw L, Propp S, Sopher BL, Taylor J, Lin A, Hermel E, Logvinova A, Chen SF, Chen S, et al: Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. J Biol Chem. 2007, 282 (41): 30150-30160. 10.1074/jbc.M705265200.PubMedCrossRef Young JE, Gouw L, Propp S, Sopher BL, Taylor J, Lin A, Hermel E, Logvinova A, Chen SF, Chen S, et al: Proteolytic cleavage of ataxin-7 by caspase-7 modulates cellular toxicity and transcriptional dysregulation. J Biol Chem. 2007, 282 (41): 30150-30160. 10.1074/jbc.M705265200.PubMedCrossRef
15.
go back to reference Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998, 94 (4): 491-501. 10.1016/S0092-8674(00)81590-1.PubMedCrossRef Li H, Zhu H, Xu CJ, Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998, 94 (4): 491-501. 10.1016/S0092-8674(00)81590-1.PubMedCrossRef
16.
go back to reference Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC: Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. The EMBO Journal. 1999, 18 (19): 5242-5251. 10.1093/emboj/18.19.5242.PubMedPubMedCentralCrossRef Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC: Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. The EMBO Journal. 1999, 18 (19): 5242-5251. 10.1093/emboj/18.19.5242.PubMedPubMedCentralCrossRef
17.
go back to reference Salvesen GS, Riedl SJ: Caspase mechanisms. Adv Exp Med Biol. 2008, 615: 13-23. 10.1007/978-1-4020-6554-5_2.PubMedCrossRef Salvesen GS, Riedl SJ: Caspase mechanisms. Adv Exp Med Biol. 2008, 615: 13-23. 10.1007/978-1-4020-6554-5_2.PubMedCrossRef
18.
go back to reference Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, et al: Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006, 125 (6): 1179-1191. 10.1016/j.cell.2006.04.026.PubMedCrossRef Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, et al: Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 2006, 125 (6): 1179-1191. 10.1016/j.cell.2006.04.026.PubMedCrossRef
19.
go back to reference Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR: Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain. 2009, 132 (Pt 4): 919-932.PubMed Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR: Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain. 2009, 132 (Pt 4): 919-932.PubMed
20.
go back to reference Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RWY, Vasuta OC, Graham RK, Hayden MR, et al: Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice. Neuron. 2010, 65 (2): 178-190. 10.1016/j.neuron.2010.01.008.PubMedCrossRef Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RWY, Vasuta OC, Graham RK, Hayden MR, et al: Early Increase in Extrasynaptic NMDA Receptor Signaling and Expression Contributes to Phenotype Onset in Huntington's Disease Mice. Neuron. 2010, 65 (2): 178-190. 10.1016/j.neuron.2010.01.008.PubMedCrossRef
21.
go back to reference Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S, Carlson E, Sagi SA, Chevallier N, Jin K, et al: Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. J Biol Chem. 1999, 274 (13): 8730-8736. 10.1074/jbc.274.13.8730.CrossRef Galvan V, Gorostiza OF, Banwait S, Ataie M, Logvinova AV, Sitaraman S, Carlson E, Sagi SA, Chevallier N, Jin K, et al: Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. J Biol Chem. 1999, 274 (13): 8730-8736. 10.1074/jbc.274.13.8730.CrossRef
22.
go back to reference Saganich MJ, Schroeder BE, Galvan V, Bredesen DE, Koo EH, Heinemann SF: Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J Neurosci. 2006, 26 (52): 13428-13436. 10.1523/JNEUROSCI.4180-06.2006.PubMedCrossRef Saganich MJ, Schroeder BE, Galvan V, Bredesen DE, Koo EH, Heinemann SF: Deficits in synaptic transmission and learning in amyloid precursor protein (APP) transgenic mice require C-terminal cleavage of APP. J Neurosci. 2006, 26 (52): 13428-13436. 10.1523/JNEUROSCI.4180-06.2006.PubMedCrossRef
23.
go back to reference Ellerby LM, Andrusiak RL, Wellington CL, Hackam AS, Propp SS, Wood JD, Sharp AH, Margolis RL, Ross CA, Salvesen GS, et al: Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem. 1999, 274 (13): 8730-8736. 10.1074/jbc.274.13.8730.PubMedCrossRef Ellerby LM, Andrusiak RL, Wellington CL, Hackam AS, Propp SS, Wood JD, Sharp AH, Margolis RL, Ross CA, Salvesen GS, et al: Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem. 1999, 274 (13): 8730-8736. 10.1074/jbc.274.13.8730.PubMedCrossRef
24.
go back to reference Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, Greene LA: beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem. 2001, 77 (1): 157-164. 10.1046/j.1471-4159.2001.t01-1-00218.x.PubMedCrossRef Troy CM, Rabacchi SA, Xu Z, Maroney AC, Connors TJ, Shelanski ML, Greene LA: beta-Amyloid-induced neuronal apoptosis requires c-Jun N-terminal kinase activation. J Neurochem. 2001, 77 (1): 157-164. 10.1046/j.1471-4159.2001.t01-1-00218.x.PubMedCrossRef
25.
go back to reference Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K, Shelanski ML: Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci. 2000, 20 (4): 1386-1392.PubMed Troy CM, Rabacchi SA, Friedman WJ, Frappier TF, Brown K, Shelanski ML: Caspase-2 mediates neuronal cell death induced by beta-amyloid. J Neurosci. 2000, 20 (4): 1386-1392.PubMed
26.
go back to reference Allen JW, Eldadah BA, Huang X, Knoblach SM, Faden AI: Multiple caspases are involved in beta-amyloid-induced neuronal apoptosis. J Neurosci Res. 2001, 65 (1): 45-53. 10.1002/jnr.1126.PubMedCrossRef Allen JW, Eldadah BA, Huang X, Knoblach SM, Faden AI: Multiple caspases are involved in beta-amyloid-induced neuronal apoptosis. J Neurosci Res. 2001, 65 (1): 45-53. 10.1002/jnr.1126.PubMedCrossRef
27.
go back to reference Wang L, Miura M, Bergeron L, Zhu H, Yuan J: Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell. 1994, 78 (5): 739-750. 10.1016/S0092-8674(94)90422-7.PubMedCrossRef Wang L, Miura M, Bergeron L, Zhu H, Yuan J: Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death. Cell. 1994, 78 (5): 739-750. 10.1016/S0092-8674(94)90422-7.PubMedCrossRef
28.
go back to reference Kumar S, Kinoshita M, Noda M, Copeland NG, Jenkins NA: Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1 beta-converting enzyme. Genes Dev. 1994, 8 (14): 1613-1626. 10.1101/gad.8.14.1613.PubMedCrossRef Kumar S, Kinoshita M, Noda M, Copeland NG, Jenkins NA: Induction of apoptosis by the mouse Nedd2 gene, which encodes a protein similar to the product of the Caenorhabditis elegans cell death gene ced-3 and the mammalian IL-1 beta-converting enzyme. Genes Dev. 1994, 8 (14): 1613-1626. 10.1101/gad.8.14.1613.PubMedCrossRef
29.
go back to reference Lamkanfi M, Declercq W, Kalai M, Saelens X, Vandenabeele P: Alice in caspase land. A phylogenetic analysis of caspases from worm to man. Cell Death Differ. 2002, 9 (4): 358-361. 10.1038/sj.cdd.4400989.PubMedCrossRef Lamkanfi M, Declercq W, Kalai M, Saelens X, Vandenabeele P: Alice in caspase land. A phylogenetic analysis of caspases from worm to man. Cell Death Differ. 2002, 9 (4): 358-361. 10.1038/sj.cdd.4400989.PubMedCrossRef
30.
go back to reference Xue D, Shaham S, Horvitz HR: The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Genes Dev. 1996, 10 (9): 1073-1083. 10.1101/gad.10.9.1073.PubMedCrossRef Xue D, Shaham S, Horvitz HR: The Caenorhabditis elegans cell-death protein CED-3 is a cysteine protease with substrate specificities similar to those of the human CPP32 protease. Genes Dev. 1996, 10 (9): 1073-1083. 10.1101/gad.10.9.1073.PubMedCrossRef
31.
go back to reference Mancini M, Machamer CE, Roy S, Nicholson DW, Thornberry NA, Casciola-Rosen LA, Rosen A: Caspase-2 is localized at the Golgi complex and cleaves golgin-160 during apoptosis. J Cell Biol. 2000, 149 (3): 603-612. 10.1083/jcb.149.3.603.PubMedPubMedCentralCrossRef Mancini M, Machamer CE, Roy S, Nicholson DW, Thornberry NA, Casciola-Rosen LA, Rosen A: Caspase-2 is localized at the Golgi complex and cleaves golgin-160 during apoptosis. J Cell Biol. 2000, 149 (3): 603-612. 10.1083/jcb.149.3.603.PubMedPubMedCentralCrossRef
32.
go back to reference Rotter B, Kroviarski Y, Nicolas G, Dhermy D, Lecomte M-C: AlphaII-spectrin is an in vitro target for caspase-2, and its cleavage is regulated by calmodulin binding. Biochem J. 2004, 378: (Pt 1):161-168.PubMedCrossRef Rotter B, Kroviarski Y, Nicolas G, Dhermy D, Lecomte M-C: AlphaII-spectrin is an in vitro target for caspase-2, and its cleavage is regulated by calmodulin binding. Biochem J. 2004, 378: (Pt 1):161-168.PubMedCrossRef
33.
go back to reference Panaretakis T, Laane E, Pokrovskaja K, Björklund A-C, Moustakas A, Zhivotovsky B, Heyman M, Shoshan MC, Grandér D: Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. Mol Biol Cell. 2005, 16 (8): 3821-3831. 10.1091/mbc.E04-10-0862.PubMedPubMedCentralCrossRef Panaretakis T, Laane E, Pokrovskaja K, Björklund A-C, Moustakas A, Zhivotovsky B, Heyman M, Shoshan MC, Grandér D: Doxorubicin requires the sequential activation of caspase-2, protein kinase Cdelta, and c-Jun NH2-terminal kinase to induce apoptosis. Mol Biol Cell. 2005, 16 (8): 3821-3831. 10.1091/mbc.E04-10-0862.PubMedPubMedCentralCrossRef
34.
go back to reference Gao Z, Shao Y, Jiang X: Essential roles of the Bcl-2 family of proteins in caspase-2-induced apoptosis. J Biol Chem. 2005, 280 (46): 38271-38275. 10.1074/jbc.M506488200.PubMedCrossRef Gao Z, Shao Y, Jiang X: Essential roles of the Bcl-2 family of proteins in caspase-2-induced apoptosis. J Biol Chem. 2005, 280 (46): 38271-38275. 10.1074/jbc.M506488200.PubMedCrossRef
35.
go back to reference McStay GP, Salvesen GS, Green DR: Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways. Cell Death Differ. 2008, 15 (2): 322-331. 10.1038/sj.cdd.4402260.PubMedCrossRef McStay GP, Salvesen GS, Green DR: Overlapping cleavage motif selectivity of caspases: implications for analysis of apoptotic pathways. Cell Death Differ. 2008, 15 (2): 322-331. 10.1038/sj.cdd.4402260.PubMedCrossRef
36.
go back to reference van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR: Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet. 2005, 14 (24): 3823-3835. 10.1093/hmg/ddi407.PubMedCrossRef van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR: Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Hum Mol Genet. 2005, 14 (24): 3823-3835. 10.1093/hmg/ddi407.PubMedCrossRef
37.
go back to reference Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR: Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci. 2005, 25 (16): 4169-4180. 10.1523/JNEUROSCI.0590-05.2005.PubMedCrossRef Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR: Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci. 2005, 25 (16): 4169-4180. 10.1523/JNEUROSCI.0590-05.2005.PubMedCrossRef
38.
go back to reference Slow EJ, van Raamsdonk J, Rogers DA, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang Y, et al: Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003, 12 (13): 1555-1567. 10.1093/hmg/ddg169.PubMedCrossRef Slow EJ, van Raamsdonk J, Rogers DA, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang Y, et al: Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet. 2003, 12 (13): 1555-1567. 10.1093/hmg/ddg169.PubMedCrossRef
39.
go back to reference O'Reilly LA, Ekert P, Harvey N, Marsden V, Cullen L, Vaux DL, Hacker G, Magnusson C, Pakusch M, Cecconi F, et al: Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. Cell Death Differ. 2002, 9 (8): 832-841. 10.1038/sj.cdd.4401033.PubMedCrossRef O'Reilly LA, Ekert P, Harvey N, Marsden V, Cullen L, Vaux DL, Hacker G, Magnusson C, Pakusch M, Cecconi F, et al: Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. Cell Death Differ. 2002, 9 (8): 832-841. 10.1038/sj.cdd.4401033.PubMedCrossRef
40.
go back to reference Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, et al: Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006, 15 (6): 965-977. 10.1093/hmg/ddl013.PubMedCrossRef Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, et al: Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006, 15 (6): 965-977. 10.1093/hmg/ddl013.PubMedCrossRef
41.
go back to reference Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M, et al: Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci. 2005, 25 (43): 9932-9939. 10.1523/JNEUROSCI.3355-05.2005.PubMedCrossRef Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M, et al: Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci. 2005, 25 (43): 9932-9939. 10.1523/JNEUROSCI.3355-05.2005.PubMedCrossRef
42.
go back to reference Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR: Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain: a journal of neurology. 2009, 132 (Pt 4): 919-932. Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR: Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain: a journal of neurology. 2009, 132 (Pt 4): 919-932.
43.
go back to reference Southwell AL, Ko J, Patterson PH: Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci. 2009, 29 (43): 13589-13602. 10.1523/JNEUROSCI.4286-09.2009.PubMedPubMedCentralCrossRef Southwell AL, Ko J, Patterson PH: Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci. 2009, 29 (43): 13589-13602. 10.1523/JNEUROSCI.4286-09.2009.PubMedPubMedCentralCrossRef
44.
go back to reference Aron AR, Watkins L, Sahakian BJ, Monsell S, Barker RA, Robbins TW: Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function. J Cogn Neurosci. 2003, 15 (5): 629-642. 10.1162/jocn.2003.15.5.629.PubMedCrossRef Aron AR, Watkins L, Sahakian BJ, Monsell S, Barker RA, Robbins TW: Task-set switching deficits in early-stage Huntington's disease: implications for basal ganglia function. J Cogn Neurosci. 2003, 15 (5): 629-642. 10.1162/jocn.2003.15.5.629.PubMedCrossRef
45.
go back to reference Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW: Executive and mnemonic functions in early Huntington's disease. Brain. 1996, 119 (Pt 5): 1633-1645.PubMedCrossRef Lawrence AD, Sahakian BJ, Hodges JR, Rosser AE, Lange KW, Robbins TW: Executive and mnemonic functions in early Huntington's disease. Brain. 1996, 119 (Pt 5): 1633-1645.PubMedCrossRef
46.
go back to reference Lalonde R, Qian S: Exploratory activity, motor coordination, and spatial learning in Mchr1 knockout mice. Behav Brain Res. 2007, 178 (2): 293-304. 10.1016/j.bbr.2007.01.006.PubMedCrossRef Lalonde R, Qian S: Exploratory activity, motor coordination, and spatial learning in Mchr1 knockout mice. Behav Brain Res. 2007, 178 (2): 293-304. 10.1016/j.bbr.2007.01.006.PubMedCrossRef
47.
go back to reference Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR: Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatr. 1995, 58 (2): 192-200. 10.1136/jnnp.58.2.192.PubMedPubMedCentralCrossRef Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR: Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington's disease. J Neurol Neurosurg Psychiatr. 1995, 58 (2): 192-200. 10.1136/jnnp.58.2.192.PubMedPubMedCentralCrossRef
48.
go back to reference Southwell AL, Ko J, Patterson PH: Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci. 2009, 29 (43): 13589-13602. 10.1523/JNEUROSCI.4286-09.2009.PubMedPubMedCentralCrossRef Southwell AL, Ko J, Patterson PH: Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci. 2009, 29 (43): 13589-13602. 10.1523/JNEUROSCI.4286-09.2009.PubMedPubMedCentralCrossRef
49.
go back to reference Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersén A, Björkqvist M, Muir C, Mackenzie IR, Hammond GL, et al: Testicular degeneration in Huntington disease. Neurobiol Dis. 2007, 26 (3): 512-520. 10.1016/j.nbd.2007.01.006.PubMedCrossRef Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersén A, Björkqvist M, Muir C, Mackenzie IR, Hammond GL, et al: Testicular degeneration in Huntington disease. Neurobiol Dis. 2007, 26 (3): 512-520. 10.1016/j.nbd.2007.01.006.PubMedCrossRef
50.
go back to reference Carroll JB, Lerch JP, Franciosi S, Spreeuw A, Bissada N, Henkelman RM, Hayden MR: Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington Disease. Neurobiol Dis. 2011 Carroll JB, Lerch JP, Franciosi S, Spreeuw A, Bissada N, Henkelman RM, Hayden MR: Natural history of disease in the YAC128 mouse reveals a discrete signature of pathology in Huntington Disease. Neurobiol Dis. 2011
51.
go back to reference Dorr AE, Lerch JP, Spring S, Kabani N, Henkelman RM: High resolution three-dimensional brain atlas using an average magnetic resonance image of 40 adult C57Bl/6J mice. NeuroImage. 2008, 42 (1): 60-69. 10.1016/j.neuroimage.2008.03.037.PubMedCrossRef Dorr AE, Lerch JP, Spring S, Kabani N, Henkelman RM: High resolution three-dimensional brain atlas using an average magnetic resonance image of 40 adult C57Bl/6J mice. NeuroImage. 2008, 42 (1): 60-69. 10.1016/j.neuroimage.2008.03.037.PubMedCrossRef
52.
go back to reference Lerch JP, Carroll JB, Dorr A, Spring S, Evans AC, Hayden MR, Sled JG, Henkelman RM: Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease. NeuroImage. 2008, 41 (2): 243-251. 10.1016/j.neuroimage.2008.02.019.PubMedCrossRef Lerch JP, Carroll JB, Dorr A, Spring S, Evans AC, Hayden MR, Sled JG, Henkelman RM: Cortical thickness measured from MRI in the YAC128 mouse model of Huntington's disease. NeuroImage. 2008, 41 (2): 243-251. 10.1016/j.neuroimage.2008.02.019.PubMedCrossRef
53.
go back to reference Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, Hayden MR, Henkelman RM: Automated deformation analysis in the YAC128 Huntington disease mouse model. NeuroImage. 2008, 39 (1): 32-39. 10.1016/j.neuroimage.2007.08.033.PubMedCrossRef Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, Hayden MR, Henkelman RM: Automated deformation analysis in the YAC128 Huntington disease mouse model. NeuroImage. 2008, 39 (1): 32-39. 10.1016/j.neuroimage.2007.08.033.PubMedCrossRef
54.
go back to reference Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, Hayden MR, Mark Henkelman R: Automated deformation analysis in the YAC128 Huntington disease mouse model. Neuroimage. 2008, 39: Lerch JP, Carroll JB, Spring S, Bertram LN, Schwab C, Hayden MR, Mark Henkelman R: Automated deformation analysis in the YAC128 Huntington disease mouse model. Neuroimage. 2008, 39:
55.
go back to reference Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC: Brain structure in preclinical Huntington's disease. Biol Psychiatry. 2006, 59 (1): 57-63. 10.1016/j.biopsych.2005.06.003.PubMedCrossRef Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC: Brain structure in preclinical Huntington's disease. Biol Psychiatry. 2006, 59 (1): 57-63. 10.1016/j.biopsych.2005.06.003.PubMedCrossRef
56.
go back to reference Sprengelmeyer R, Lange H, Hömberg V: The pattern of attentional deficits in Huntington's disease. Brain. 1995, 118 (Pt 1): 145-152.PubMedCrossRef Sprengelmeyer R, Lange H, Hömberg V: The pattern of attentional deficits in Huntington's disease. Brain. 1995, 118 (Pt 1): 145-152.PubMedCrossRef
57.
go back to reference Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinsztein DC, Robbins TW, Sahakian BJ: Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain. 1998, 121 (Pt 7): 1329-1341.PubMedCrossRef Lawrence AD, Hodges JR, Rosser AE, Kershaw A, ffrench-Constant C, Rubinsztein DC, Robbins TW, Sahakian BJ: Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain. 1998, 121 (Pt 7): 1329-1341.PubMedCrossRef
58.
go back to reference Van Raamsdonk JM, Pearson J, Bailey CDC, Rogers DA, Johnson GVW, Hayden MR, Leavitt BR: Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem. 2005, 95 (1): 210-220. 10.1111/j.1471-4159.2005.03357.x.PubMedCrossRef Van Raamsdonk JM, Pearson J, Bailey CDC, Rogers DA, Johnson GVW, Hayden MR, Leavitt BR: Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. J Neurochem. 2005, 95 (1): 210-220. 10.1111/j.1471-4159.2005.03357.x.PubMedCrossRef
59.
go back to reference Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, Honer WG, Hayden MR, Leavitt BR: Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol. 2005, 196 (2): 266-272. 10.1016/j.expneurol.2005.07.021.PubMedCrossRef Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, Honer WG, Hayden MR, Leavitt BR: Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol. 2005, 196 (2): 266-272. 10.1016/j.expneurol.2005.07.021.PubMedCrossRef
60.
go back to reference Group HS: Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology. 2006, 66 (3): 366-372.CrossRef Group HS: Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology. 2006, 66 (3): 366-372.CrossRef
61.
go back to reference Henkelman RM, Baghdadi L, Sled JG: Presentation of 3D isotropic imaging data for optimal viewing. Magn Reson Med. 2006, 56 (6): 1371-1374. 10.1002/mrm.21077.PubMedCrossRef Henkelman RM, Baghdadi L, Sled JG: Presentation of 3D isotropic imaging data for optimal viewing. Magn Reson Med. 2006, 56 (6): 1371-1374. 10.1002/mrm.21077.PubMedCrossRef
62.
go back to reference Dorr AE, Lerch JP, Kabani N, Henkelman RM: High resolution three-dimensional brain atlas using an average magnetic resonance image of 40 adult C57Bl/6J mice. Neuroimage. 2008, 42 (1): 60-69. 10.1016/j.neuroimage.2008.03.037.PubMedCrossRef Dorr AE, Lerch JP, Kabani N, Henkelman RM: High resolution three-dimensional brain atlas using an average magnetic resonance image of 40 adult C57Bl/6J mice. Neuroimage. 2008, 42 (1): 60-69. 10.1016/j.neuroimage.2008.03.037.PubMedCrossRef
63.
go back to reference Collins D, Holmes C, Peters T, Evans A: Automatic 3-D model-based neuroanatomical segmentation. Human Brain Mapping. 1995, 3 (3): 190-208. 10.1002/hbm.460030304.CrossRef Collins D, Holmes C, Peters T, Evans A: Automatic 3-D model-based neuroanatomical segmentation. Human Brain Mapping. 1995, 3 (3): 190-208. 10.1002/hbm.460030304.CrossRef
64.
go back to reference Lerch J, Yiu A, Bohbot V, Henkelman R, Josselyn S, Sled J: Morris water maze training induces changes in brain shape detectable by MRI. Society for Neuroscience. 2007, 104530- Lerch J, Yiu A, Bohbot V, Henkelman R, Josselyn S, Sled J: Morris water maze training induces changes in brain shape detectable by MRI. Society for Neuroscience. 2007, 104530-
65.
go back to reference Team RDC: R: A Language and Environment for Statistical Computing. 2009 Team RDC: R: A Language and Environment for Statistical Computing. 2009
66.
go back to reference Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, et al: Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006, 15 (6): 965-977. 10.1093/hmg/ddl013.PubMedCrossRef Hodges A, Strand AD, Aragaki AK, Kuhn A, Sengstag T, Hughes G, Elliston LA, Hartog C, Goldstein DR, Thu D, et al: Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006, 15 (6): 965-977. 10.1093/hmg/ddl013.PubMedCrossRef
Metadata
Title
Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease
Authors
Jeffrey B Carroll
Amber L Southwell
Rona K Graham
Jason P Lerch
Dagmar E Ehrnhoefer
Li-Ping Cao
Wei-Ning Zhang
Yu Deng
Nagat Bissada
R Mark Henkelman
Michael R Hayden
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Molecular Neurodegeneration / Issue 1/2011
Electronic ISSN: 1750-1326
DOI
https://doi.org/10.1186/1750-1326-6-59

Other articles of this Issue 1/2011

Molecular Neurodegeneration 1/2011 Go to the issue